|
Status |
Public on Aug 02, 2012 |
Title |
SKOV3, IFN, 6h, rep1 |
Sample type |
RNA |
|
|
Source name |
SKOV3 cells, IFN treated 6h
|
Organism |
Homo sapiens |
Characteristics |
time: 6h treatment: IFN cell line: SKOV3 human ovarian adenocarcinoma cell line
|
Treatment protocol |
Confluent cells were treated with interferon-alpha (500 U/ml), U0126 (20uM) or both for 6 or 12 hours.
|
Growth protocol |
Cells were plated 6-well plates the day prior to treatment.
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted with TriZOL (Invitrogen) following the manufacturer's protocol. RNA was treated with Turbo DNA-free to remove genomic DNA contamination.
|
Label |
biotin
|
Label protocol |
500 ng of RNA was used for labeling using the Ambion WT kit. Labeling was performed by The Centre for Applied Genomics (Toronto, Canada) according to the manufacturer's protocol.
|
|
|
Hybridization protocol |
Hybridization was performed by The Centre for Applied Genomics (Toronto, Canada) according to the manufacturer's protocol (FS450_0007).
|
Scan protocol |
Scanning was performed with the Affymetrix GeneChip Scanner 3000 by The Centre for Applied Genomics (Toronto, Canada) according to the manufacturer's protocol.
|
Description |
gene expression data from SKOV3 cells treated with Inteferon-alpha for 6 hours
|
Data processing |
Data were analyzed using Bioconducter 2.6. Pre-processing was performed with the Oligo package using rma normalization. Each cell type was analyzed independently, relative to the time-matched control.
|
|
|
Submission date |
Jul 28, 2011 |
Last update date |
Aug 02, 2012 |
Contact name |
Sherri L Christian |
E-mail(s) |
[email protected]
|
Phone |
(709)864-8550
|
Organization name |
Memorial University of Newfoundland
|
Department |
Biochemistry
|
Street address |
232 Elizabeth Ave
|
City |
St. John's |
State/province |
Newfoundland |
ZIP/Postal code |
A1B3X9 |
Country |
Canada |
|
|
Platform ID |
GPL6244 |
Series (1) |
GSE31019 |
Suppression of IFN-induced transcription underlies IFN defects generated by activated Ras/MEK in human cancer cells |
|